Mylan reaches deal with Herceptin

Mylan NV announced Monday a deal with Genentech Inc. and F. Hoffmann-La Roche Ltd. that will clear the way for Mylan to launch its version of a drug to treat breast cancer. Financial terms of the deal between Mylan (Nasdaq: MYL) and Genentech and F. Hoffmann-La Roche weren't announced, although Mylan will receive a global license to launch trastuzumab, the generic name for Herceptin. It also will withdraw challenges to patents by Genentech. The license deal does not include Mexico, Brazil or Japan,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news